Toni Choueiri, MD

Medical Oncology

Toni Choueiri, MD

View Profile

Related Videos

COVID-19 Vaccine Study in Cancer Patients Video

COVID-19 Vaccine Study in Cancer Patients

Dana-Farber researchers are leading a study that looks at the effects of the COVID-19 vaccine in cancer patients.

Choueiri and Motzer Chat on CheckMate-9ER and Other RCC Research Video

Choueiri and Motzer Chat on CheckMate-9ER and Other RCC Research

In our exclusive interview, Dr. Choueiri and Dr. Motzer discuss the clinical implications of the phase 3 CheckMate-9ER trial in advanced renal cell carcinoma and how to best use the combination in practice.

Phase 2 Study of the Oral Hypoxia-Inducible Factor 2a (HIF-2a) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) Video

Phase 2 Study of the Oral Hypoxia-Inducible Factor 2a (HIF-2a) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Kidney Cancer Research: HIF-2a drug combination shows promise in previously treated patients with clear cell renal cell carcinoma. Preliminary results presented by Toni Chouieiri, MD at ASCO #GU21

Phase 3 Trial of Lenvatinib (LEN) Plus Pembrolizumab (PEMBRO) or Everolimus (EVE) Versus Sunitinib (SUN) Monotherapy as a First-Line Treatment for Patients (pts) with Advanced Renal Cell Carcinoma (RCC) (CLEAR Study Video

Phase 3 Trial of Lenvatinib (LEN) Plus Pembrolizumab (PEMBRO) or Everolimus (EVE) Versus Sunitinib (SUN) Monotherapy as a First-Line Treatment for Patients (pts) with Advanced Renal Cell Carcinoma (RCC) (CLEAR Study

Kidney Cancer Research: Toni Choueiri, MD details results from the phase 3 CLEAR study that showed significant benefits from the combination of lenvatinib, an oral kinase inhibitor, and pembrolizumab, a checkpoint inhibitor in advanced kidney cancer.